Development of predictive pharmacokinetic simulation models for drug discovery.

As discovery chemistry produces increased numbers of potential drug compounds, the use of ADME (absorption, distribution, metabolism, and excretion) properties is becoming increasingly important in the drug selection and promotion process. A computer simulation model has been developed and validated to predict ADME outcomes, such as rate of absorption, extent of absorption, etc. using a limited number of in vitro data inputs. The oral bioavailability of ganciclovir in dogs and humans was simulated using a physiologically based model that utilized many biopharmaceutically relevant parameters, such as the concentration of ganciclovir in the duodenum, jejunum, ileum, and colon at various dose levels and solubility values. The simulations were run and compared to dog and human in vivo data. The simulation results demonstrated that the low bioavailability of ganciclovir is limited by compound solubility rather than permeability due to partitioning as previously speculated. This technology provides a breakthrough in in silico prediction of absorption and with its continued development and improvement, will aid drug discovery and development scientists to produce better pharmaceutical products.

[1]  Susan Budavari,et al.  The Merck index , 1998 .

[2]  W R Gillespie,et al.  Convolution-based approaches for in vivo-in vitro correlation modeling. , 1997, Advances in experimental medicine and biology.

[3]  J. C. Martin,et al.  Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine , 1983, Antimicrobial Agents and Chemotherapy.

[4]  S. Walker,et al.  Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). , 1988, British journal of clinical pharmacology.

[5]  G L Amidon,et al.  Novel approach to the analysis of in vitro-in vivo relationships. , 1996, Journal of pharmaceutical sciences.

[6]  P. Artursson,et al.  Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. , 1991, Biochemical and biophysical research communications.

[7]  J. Mcainsh,et al.  Pharmacokinetic studies with atenolol in the dog , 1983, Biopharmaceutics & drug disposition.

[8]  D. Jung,et al.  Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. , 1995, Clinical therapeutics.

[9]  G L Amidon,et al.  Saturable small intestinal drug absorption in humans: modeling and interpretation of cefatrizine data. , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[10]  J. Polli,et al.  Prediction of dissolution-absorption relationships from a dissolution/Caco-2 system. , 1999, International journal of pharmaceutics.

[11]  S. Itai,et al.  In vitro dissolution tests corresponding to the in vivo dissolution of clarithromycin tablets in the stomach and intestine. , 1995, Chemical & pharmaceutical bulletin.

[12]  H. Frey,et al.  Pharmacokinetics of naproxen in the dog. , 1981, American journal of veterinary research.

[13]  Sietsema Wk,et al.  The absolute oral bioavailability of selected drugs , 1989 .

[14]  J. C. Martin,et al.  9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine: a new potent and selective antiherpes agent. , 1983, Journal of medicinal chemistry.

[15]  G. Grass,et al.  Simulation models to predict oral drug absorption from in vitro data , 1997 .

[16]  J Devane,et al.  A new approach to modelling the relationship between in vitro and in vivo drug dissolution/absorption. , 1999, Statistics in medicine.

[17]  D. Jung,et al.  Effect of Food on the Relative Bioavailability of Oral Ganciclovir , 1996, Journal of clinical pharmacology.

[18]  S. Spector,et al.  Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group. , 1995, The Journal of infectious diseases.

[19]  T. Kennedy Managing the drug discovery/development interface , 1997 .

[20]  G. Amidon,et al.  Absorption potential: estimating the fraction absorbed for orally administered compounds. , 1985, Journal of pharmaceutical sciences.

[21]  J. Dressman,et al.  Mixing-tank model for predicting dissolution rate control or oral absorption. , 1986, Journal of pharmaceutical sciences.

[22]  PHARMACOKINETIC STUDIES , 1976 .